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Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous tumor that present
considerable challenges due to its size and deep location. As a consequence, the majority
of patients with high-grade RLS will develop locally recurrent disease following surgery,
and this constitutes the cause of death in most patients. Here, we review current insights
and controversies regarding histology, molecular biology, extent of surgery, (neo)adjuvant
treatment, and systemic treatment including novel targeted agents in RLS.
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INTRODUCTION
ANATOMY OF THE RETROPERITONEUM
The retroperitoneum (RP) forms together with the pre-
peritoneum the extraperitoneal space. The RP space is an almost
virtual and expandable space, defined anteriorly by the peritoneal
extensions anchoring the transverse colon, the small bowel, as well
as the ascending and descending colon, part of the duodenum,
part of the pancreas, and a part of the liver (1, 2). The RP can
be divided into perirenal and (anterior and posterior) pararenal
spaces and contains several vital structures: the retroperitoneal
organs (the pancreas, kidneys, adrenals, and part of the duodenum,
ascending and descending colon), the greater abdominal vessels,
the abdominal lymphatics, six major nerves and the autonomic
(sympathetic) lumbar chains, and the connective tissue of fasciae,
with the White line of Toldt as the fusion between the mesocolon
and posterior RP (1).
Masses encountered in the RP can be benign, primary malig-
nant, or metastatic. Primary retroperitoneal tumors (PRT) are
those originating in the RP space, but not from the RP organs.
Probably, the first report of a PRT was by Giovanni Battista
Morgagni (1682–1771), describing in 1761, a retroperitoneal lipo-
matous tumor found at the autopsy of a 60-year-old woman
(3). But it was Jean Fréderic Lobstein (1777–1835) of Strasbourg
who launched the actual term “PRT” in his Traité d’anatomie
pathologique (1829) (4). About three out of four PRTs are malig-
nant (2, 5). PRTs are classified by their similarity with a certain
type of mesenchymal tissue, with up to 2/3 being of mesodermal
origin. Over 80% of mesodermal PRTs are malignant. Soft tissue
sarcomas (STS), defined by James Stephen Ewing (1866–1943) in
his book Neoplastic Diseases (1919) as “unusual malignant tumors
composed of cells of the mesodermal/connective tissue type” (6), rep-
resent an extremely diverse group of more than 50 different types
and subtypes of neoplasms, derived from adipose tissue, mus-
cle, connective, vascular, or deep skin tissue and also bone and
cartilage (2, 7–9). Although neural tissue is of (neuro-)ectodermal
origin, malignant peripheral nerve sheath tumors (MPNST) are
very often classified under STS as well.
NATURAL HISTORY
Soft tissue sarcoma accounts for <1% of all malignant tumors in
adults (2, 10), with an estimated incidence of 4–5/100,000/year in
Europe (11). About 10–15% of adult STS are located in the RP (2,
12). Liposarcoma is the most common variant and accounts for
20% of all STS, and over 50% of RP sarcomas (13). Commonly
classified on their histologic basis (14), STS are very heteroge-
neous and carry a varying prognosis. The natural behavior and
outcome of STS are dependent of the age of the patient, anatom-
ical site and depth, size, and resectability of the tumor, as well as
of histology, grade, nodal disease, and distant metastasis (DM)
(10). Most retroperitoneal soft tissue sarcomas (RPS), even of
important size, rarely metastasize (2): only about 10% of RPS are
found to have metastatic disease at presentation, which is mostly
hematogenous and equally distributed to the lungs or the liver (2,
5). The presence of DM is an adverse prognostic factor for the
outcome of all STS. In RPS, DM occurs in approximately 20–25%
of patients and once DM is found, overall survival is poor, at a
median of 13 months (10). DM in STS and RPS is largely depen-
dent on the tumor’s malignancy grade (see below) (10). Because
most RPS are low-grade, DM is rare, and the main problem is
local control and recurrence. Their large size and deep location
in an anatomically complex area containing a number of vital
structures, makes the resectability of RPS difficult and sometimes
impossible (5, 12). Patients who undergo complete (macroscopic)
or even compartmental resection (R0 or R1) of the primary tumor
have an improved prognosis with a 5-year overall survival of 54–
70% (2, 15), yet 41–50% of these patients will demonstrate locally
recurrent disease within 5 years after surgery (2, 5, 15). A review
from the Memorial Sloan-Kettering Cancer Center (New York, NY,
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Table 1 | Predisposing genetic alterations for soft tissue sarcoma.
Common name Incidence Gene mutation Chrom. Heredity Sarcoma type Reference
Neurofibromatosis type 1 1/2.000–4.000 NF1 17q11.2 Autos. Dom. MPNST (22)
Li-Fraumeni syndrome 1/5.000–20.000 TP53, hCHK2 17p13.1 Autos. Dom. RMS, FS, UPS, OS,
LPS, LMS a.o.
FAP/Gardner syndrome 1/8.300–13.000 APC, MYH 5q22.2 Autos. Dom. Desmoids (16% of pts) (23)
Beckwith–Wiedemann-syndrome 1/13.700 NSD1, CDKN1C, H19 11p15, 5q35 Autos. Dom. aRMS, eRMS
Hereditary retinoblastoma 1/15.000–23.000 RB1 13q14 Autos. Dom. Various STS
Werner syndrome 3/million WRN 8p12 Autos. Rec. Various STS (24)
Costello syndrome 115 pts in 2003 HRAS 11p15.5 Autos. Dom. eRMS in 10/103 (25)
Nijmegen breakage syndrome Unknown NBS1 8q21.3 Autos. Rec. RMS
Chrom., chromosome; Autos. Dom., autosomal dominant inheritance; Autos. Rec., autosomal recessive inheritance; MPNST, malignant peripheral nerve sheath
tumor; RMS, rhabdomyosarcoma; aRMS, alveolar rhabdomyosarcoma; eRMS, embryonal rhabdomyosarcoma; pts, patients; FAP, familial adenomatous polyposis
[modified from Ref. (16)].
USA), the Royal Marsden Hospital (London, UK), and the French
national multicenter study (10, 12, 13, 15) indicated that after more
than 5 years, and even after complete macroscopic excision, local
recurrence of RPS affects 60–70% of patients and is usually the
cause of death (12).
PREDISPOSING FACTORS
Most STS and especially RPS have no clearly identified cause (10).
However, some predisposing factors have been identified: genetic
alterations and exposure to radiation or chemical substances. The
most important specific and non-specific genetic alterations pre-
disposing to STS are listed in Table 1 (16). These genetically
predisposed patients are even more at risk when exposed to ion-
izing radiation (17). In the general population, and especially
in childhood (17–19), repeated computed tomography (CT)-
scanning (18) and especially high dose ionizing radiation [as used
in external beam radiation therapy (EBRT)] are associated with
a higher risk of developing STS, with an estimated incidence of
5% after therapeutic radiation, e.g., for breast cancer, malignant
lymphoma, and pediatric cancers (20, 21). The exact mechanism
of STS development after EBRT remains, however, unknown (10).
Most radiation-associated STS are high-grade/poorly differenti-
ated and are found at the edge of the radiation field, with median
latency periods of more than 8 years (range 6–20); mainly fibrosar-
coma, osteogenic sarcoma, angiosarcoma, leiomyosarcoma, and
undifferentiated pleomorphic sarcoma have been described after
EBRT (10, 20). Toxic exposures to chemical agents have also
lead to the development of STS, but this is at present mostly of
historic interest and consisted mainly of exposure to phenoxy-
acetic acid/herbicides, thorium bromide/thorotrast, vinyl chlo-
ride, arsenic, asbestos, androgenic-anabolic steroids, dioxins, and
chlorophenoles (20).
CLINICAL PRESENTATION
Patients presenting with RPS are usually in their mid-fifties
(median age 56 years) (5, 12, 13, 15, 21, 26–36), but RPS have
been described to occur at all ages (2–98 years) (2, 5, 13, 15, 21,
26, 28, 31–33, 35–40). The gender distribution is supposedly equal
(10, 12, 21), although some large retrospective series suggest a
small surplus of female patients (mean 1.26M:1F) (2, 5, 13, 15,
26, 31–35, 37, 39, 40). Because the RP is a deep, expandable space
without many bony boundaries, slowly growing tumors generally
do not quickly cause signs or symptoms and may therefore grow to
an important size before being discovered by increased abdominal
girth, a palpable lump, or because of compression (causing gas-
trointestinal, urologic, or neurological symptoms). The majority
(>75%) of PRT and RPS present “late,” with an important size.
RPS is probably the largest tumors found in the human body (2).
In fact, RPS measuring <5 cm is considered rare (35). RPS gener-
ally measure>5 cm, and mostly>10 cm diameter at presentation
(34, 36). In the largest series of prospectively followed RPS, Lewis
et al. found 94% of these tumors exceeding 5 cm in diameter and
60% exceeding 10 cm (2, 5). About 20–50% of RPS even exceed
20 cm in diameter at the time of resection (2, 15, 26, 30–33, 40,
41). Although probably decreasing with time [because of more
widespread use of CT and magnetic resonance imaging (MRI)]
between 60% (2, 39) and 80% (5, 12) of patients are believed to
present with a palpable abdominal mass, and half of the patients
have “pain” at presentation (21).
DIAGNOSTIC WORKUP
The diagnosis and treatment of STS mandates a multidiscipli-
nary approach ideally carried out in reference centers treating a
high number of patients annually (11). Different imaging studies
can be used in the evaluation of PRT/RPS: conventional radi-
ographies of the abdomen usually indicate displacement of bowel
and altered intestinal aeration, and may show signs of calcifica-
tion in the tumoral mass (suggestive of teratoma). Ultrasound is
useful as a quick first evaluator of abdominal complaints, but is
of limited value for in-depth evaluation of RP masses, especially
in adults with increased abdominal girth/obesity. Doppler/duplex
ultrasound may offer additional information on the patency
of the femoral and iliac vessels and of the inferior caval vein
(ICV), especially in case of suspicion of partial or complete deep
venous thrombosis due to vascular compression. The diagnostic
investigation of choice to evaluate PRT/RPS is contrast-enhanced
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CT-scanning or MRI of the abdomen and pelvis (11, 12, 21, 42).
They will determine the anatomical location of the tumor, its size,
and probable origin, the relationship of the tumor to adjacent
visceral and neurovascular structures, possible compression or
invasion, and the presence or absence of transperitoneal spread
or liver or lung metastases (12, 43). Liposarcomas demonstrate
a characteristic appearance on CT and MRI with a predomi-
nantly fatty component (12). MRI does not cause added radiation
exposure and may be specifically required under certain circum-
stances (12), e.g., in pediatric patients, in cases of myxoid or round
cell liposarcoma (MRI of the spine, because of the higher risk
for spinal metastasis compared to other STS), or in alveolar soft
part sarcomas and angiosarcomas (MRI of the brain, for their
propensity to metastasize to the brain especially in the presence
of pulmonary metastasis) (44). MRI cannot, however, reliably
distinguish between benign and malignant tissue, but diffusion-
weighted MRI (DW-MRI) seems a very promising technique and
is under study (12, 43, 45).
The “staging” investigation of choice for the detection of DM
is contrast-enhanced CT-scan of the chest and abdomen (12).
18F-Fluorodeoxyglucose (FDG)-positron emission tomography
(PET) – CT scan may provide additional functional/biological
information about the retroperitoneal tumor and may possi-
bly differentiate a high-grade from a low-grade STS (46). Apart
from grading, FDG-PET may also aid in staging (detection of
metastases), restaging and in the evaluation of treatment response
and follow-up, by detecting residual masses or recurrences after
attempted radical surgery for STS. In a recent study of 102 STS
at UCLA, the tumor glycolytic phenotype correlated significantly
with the histologic grade in 91% of tumors, which may offer
prognostic significance – although FDG-PET could not reliably
distinguish among French Fédération Nationale des Centers de
Lutte contre le Cancer (FNCLCC)-grade 2 and grade 3 STS and
the various subtypes. When regarding the liposarcomas studied, in
6 of 16 (38%), there was a SUVmax<2.5 g/mL, suggesting that for
this STS-subtype, FDG-PET-based treatment monitoring might
be difficult. Further prospective studies on the value of PET for
STS are underway (44).
CLASSIFICATION, STAGING, AND GRADING
The distribution of sarcoma subtypes in the RP differs from other
localizations, with a predominant role (75–85%) for liposarcoma
and leiomyosarcoma. RPS is classified using the World Health
Organization (WHO) Classification of soft tissue tumors (Table 2)
(14). Based on its histologic type and subtype, the tumor is clas-
sified into one of four categories: benign, intermediate (locally
aggressive), intermediate (rarely metastasing), and malignant (14).
Different staging systems have been in use for predicting the sys-
temic outcomes of patients with STS, but a specific staging system
for RPS is not (yet) available. The revised UICC/AJCC-7 cancer
staging system for the prognostic classification of sarcomas is the
most commonly used; since 1977 this includes the histologic grade
(Table 3) (48). Other staging systems include the “surgical staging
system” (SSS) by Enneking and the Musculoskeletal Tumor Soci-
ety (49) and the postsurgical classification system by the Sarcoma
Disease Management Team at Memorial Sloan-Kettering Cancer
Center (MSK-system) (50).
Table 2 | WHO classification of soft tissue tumors of intermediate
malignant potential and malignant soft tissue tumors.
Adipocytic tumors
Intermediate (locally aggressive)
Atypical lipomatous tumor/well-differentiated liposarcoma
Malignant
Dedifferentiated liposarcoma
Myxoid/round cell liposarcoma
Pleomorphic liposarcoma
Mixed-type liposarcoma
Liposarcoma, not otherwise specified
Fibroblastic/myofibroblastic tumors
Intermediate (locally aggressive)
Superficial fibromatoses (palmar/plantar)
Desmoid-type fibromatoses
Lipofibromatosis
Intermediate (rarely metastasizing)
Solitary fibrous tumor and hemangiopericytoma (including lipomatous
hemangiopericytoma)
Inflammatory myofibroblastic tumor
Low-grade myofibroblastic sarcoma
Myxoinflammatory fibroblastic sarcoma
Infantile fibrosarcoma
Malignant
Adult fibrosarcoma
Myxofibrosarcoma
Low-grade fibromyxoid sarcoma/hyalinizing spindle cell tumor
Sclerosing epithelioid fibrosarcoma
So-called fibrohistiocytic tumors
Intermediate (rarely metastasizing)
Plexiform fibrohistiocytic tumor
Giant cell tumor of soft tissues
Malignant
Pleomorphic malignant fibrous histiocytoma (MFH)/undifferentiated
pleomorphic sarcoma
Giant cell MFH/undifferentiated pleomorphic sarcoma with giant cells
Inflammatory MFH/undifferentiated pleomorphic sarcoma with
prominent inflammation
Smooth muscle tumors
Malignant
Leiomyosarcoma
Skeletal muscle tumors
Malignant
Embryonal rhabdomyosarcoma (including spindle cell, botryoid,
anaplastic)
Alveolar rhabdomyosarcoma (including solid, anaplastic)
Pleomorphic rhabdomyosarcoma
Vascular tumors
Intermediate (locally aggressive)
Kaposiform hemangioendotheliomaa
Intermediate (rarely metastasizing)
Retiform hemangioendothelioma
(Continued)
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Table 2 | Continued
Papillary intralymphatic angioendothelioma
Composite hemangioendothelioma
Malignant
Epithelioid hemangioendothelioma
Angiosarcoma of soft tissue
Tumors of peripheral nerves
Malignant
Malignant peripheral nerve sheath tumor
Epithelioid malignant peripheral nerve sheath tumor
Chondro-osseous tumors
Malignant
Mesenchymal chondrosarcoma
Extraskeletal osteosarcoma
Tumors of uncertain differentiation
Intermediate (rarely metastasizing)
Angiomatoid fibrous histiocytoma
Ossifying fibromyxoid tumor (including atypical/malignant)
Mixed tumor/myoepithelioma/parachordoma
Malignant
Synovial sarcoma
Epithelioid sarcoma
Alveolar soft part sarcoma
Clear cell sarcoma of soft tissue
Extraskeletal myxoid chondrosarcoma (“chordoid” type)
Primitive neuroectodermal tumor (PNET)/extraskeletal Ewing tumor
Peripheral primitive neuroectodermal tumor (pPNET)
Extraskeletal Ewing tumor
Desmoplastic small round cell tumor
Extra-renal rhabdoid tumor
Malignant mesenchymoma
Neoplasms with perivascular epithelioid cell differentiation (PEComa)
Clear cell myomelanocytic tumor
Intimal sarcoma
aSince the last edition of the WHO classification, two cases of well-documented
regional metastasis of kaposiform hemangioendothelioma have been reported
(47) raising the issue of whether or not kaposiform hemangioendothelioma might
be more appropriately included in the category of “intermediate (rarely metas-
tasizing)” instead of “intermediate (locally aggressive).” This will undoubtedly be
addressed in the next WHO classification of tumors of soft tissue.
Histologic grade represents the most important indicator of
metastatic risk and OS in adult STS. The main objective of grading
is to select patients for adjuvant chemotherapy (51). The concept
of histological grade in sarcoma was introduced by Broders in
1920 and since then, various 2-, 3-, or 4-tier grading systems have
been in use. There is at present no single generally agreed upon
grading system for STS. Since the 1980s, the FNCLCC (52, 53)
and the US National Cancer Institute (NCI) (54) systems are the
most commonly used grading systems for STS (Table 4). Both
are 3-grade systems based on histologic tumor differentiation,
mitotic rate/activity, and percentage of tumor necrosis. The NCI
system also requires quantification of cellularity and pleomor-
phism for certain sarcoma subtypes, which is difficult to determine
objectively. The UICC/AJCC-7 STS staging system is, however, not
fully adapted for RPS. As the majority of RPS are large and deeply
situated, the prognostic value of “T” (size and depth) is less applic-
able (all are T2b) and the same is true for “N,” as most RPS do not
develop lymphatic metastasis. The system is not applicable for local
recurrences (very common in RPS) and grading remains difficult
with demonstrable interobserver discordances, even among expe-
rienced pathologists. Therefore, the surgical oncology team from
MD Anderson Cancer Center (Houston, TX, USA) proposed in
2009 a novel practical “histology-based prognostic system” to pre-
dict overall survival in all RPS patients (34). This system stratifies
RPS patients into three risk groups according to tumor histol-
ogy, with “Atypical lipomatous tumor” (ALT, well-differentiated
liposarcoma) having the best prognosis, “non-ALT liposarcoma”
(non-ALT LPS) having the worst overall survival and “Other” his-
tology (non-LPS) having an intermediate prognosis. This system is
also applicable for recurrent disease, and further risk stratification
can still be determined within each of the groups (34).
On the other hand, as for other neoplasms, molecular markers
hold also great promise for refining our ability to establish early
prognosis and to predict response to treatment in STS/RPS (“mol-
ecular grading”) (51). Molecular profiling analysis by microarray
technology has been performed in STS and a 67-gene expression
signature called CINSARC has recently been identified as a clin-
ically applicable prognostic marker (51). However, the value of
CINSARC for predicting the response to treatment is not yet
known and will soon be validated in prospective independent
series (51). Since almost a decade, cancer nomograms have been
developed, mainly instigated by the Sarcoma Disease Management
Team of MSKCC. Nomograms are being increasingly accepted to
predict risk of recurrence and disease-specific death, and to aid the
clinician in counseling patients and planning for surveillance and
follow-up (13). Nomograms for RPS and liposarcoma of the RP
have recently been published by different teams, based on the his-
tologic subtype, margin of resection, contiguous organ resection,
and age as prognostic markers for survival.
HISTOLOGY AND MOLECULAR BIOLOGY
The histological classification of liposarcoma has evolved sig-
nificantly over past several decades, in large part owing to the
advances in our understanding of its molecular genetics. The
recently updated World Health Organization (WHO) classifica-
tion of soft tissue and bone tumors recognizes four major liposar-
coma subtypes: atypical lipomatous tumor/well-differentiated
liposarcoma [which includes the adipocytic (or lipoma-like), scle-
rosing, inflammatory and spindle cell variants], dedifferentiated
liposarcoma, myxoid liposarcoma, and pleomorphic liposarcoma
(Figures 1–4) (55, 56). These four main subgroups are charac-
terized by distinctive morphologies, as well as unique genetic
findings. A fifth subtype (the so-called “mixed or combined
liposarcoma”), which was still a separate entity in the 2002 WHO
classification, has been removed from the most recent 2013 WHO
classification, based on the consensus view that those rare cases
probably represent examples of (variants of) dedifferentiated
liposarcoma. It is important to emphasize that atypical lipoma-
tous tumor and well-differentiated liposarcoma are synonyms,
describing lesions, which are identical both morphologically and
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Table 3 | Sarcoma staging system, seventh edition of the American Joint Committee on Cancer/International Union against Cancer
(UICC/AJCC-7, 2010).
T: primary tumor
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor ≤5 cm
T1a Superficial tumor (above the non-invaded fascia
T1b Deep tumor (under the fascia or with invasion of the fascia)
T2 Tumor >5 cm
T2a Superficial tumor
T2b Deep tumor (retroperitoneum= always deep)
N: regional lymph nodes
Nx Lymph node status unknown
N0 No regional lymph nodes
N1 Regional lymph node metastasis
M: distant metastasis
Mx Distant metastasis unknown
M0 No distant metastasis
M1 Distant metastasis
G: histopathological grading
TNM-two grade system Three grade systems Four grade systems
Gx Grade cannot be assessed
Low grade Grade 1 G1 Well-differentiated
G2 Moderately differentiated
High grade Grade 2 G3 Poorly differentiated
Grade 3 G4 Undifferentiated
Stage grouping
Stage Ia T1a N0 M0 Low grade
T1b N0 M0 Low grade
Stage Ib T2a N0 M0 Low grade
T2b N0 M0 Low grade
Stage IIa T1a N0 M0 High grade
T1b N0 M0 High grade
Stage Iib T2a N0 M0 High grade
Stage III T2b N0 M0 High grade
Stage IV Any T N1 M0 Any grade
Any T Any N M1 Any grade
Remark: for bone and soft tissue sarcoma, preference is given to a 2-tier instead of 3- or 4-tier system: low versus high grade.
karyotypically. Use of the term atypical lipomatous tumor is deter-
mined principally by tumor location and resectability. In sites
such as the RP, it is usually impossible to obtain a wide tumor
free surgical excision margin of more than 2 cm. In such cases,
local recurrence is common and often leads to death, even in the
absence of dedifferentiation or metastasis. At these sites, thus, the
term well-differentiated liposarcoma is used rather than atypical
lipomatous tumor (55, 56). Histopathology is the gold standard
in the diagnostic traject of lipomatous tumors. In addition to
tumor size and anatomic location, one of the most important
determining factors for the prognosis of liposarcoma patients
is the histological liposarcoma subtype, further underlining the
importance of correct subclassification. However, establishing the
correct lipomatous tumor subtype can be laborious and requires in
some instances a histological assessment together with immuno-
histochemistry and molecular analyses using fluorescence in situ
hybridization (FISH), polymerase chain reaction (PCR), mul-
tiplex ligation-dependent probe amplification (MLPA), and/or
array comparative genomic hybridization (aCGH). Finally, with
a growing number of molecularly targeted agents in oncology,
molecular testing will become increasingly important in guiding
treatment strategies of liposarcomas in the near future.
The two by far most common (lipo)sarcoma subtypes in the
RP are the well-differentiated liposarcoma (Figure 1) and dedif-
ferentiated liposarcoma, followed by the leiomyosarcoma. Primary
myxoid liposarcomas, occurring predominantly in the lower limbs
of young to middle-aged adults, are extremely rare and may
be “non-existing” in the RP. Therefore, a diagnosis of primary
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Table 4 |The French Fédération Nationale des Centers de Lutte Contre
le Cancer (FNCLCC) Grading System.
Tumor differentiation
Score 1 Sarcomas that closely resemble normal adult mesenchymal
tissues
Score 2 Sarcomas for which histologic typing is certain
Score 3 Embryonal and undifferentiated sarcomas, synovial sarcoma, and
sarcomas of uncertain differentiation
Mitotic count
Score 1 0–9 mitoses/10 hpf
Score 2 10–19 mitoses/10 hpf
Score 3 ≥20 mitoses/10 hpf
Tumor necrosis
Score 0 No necrosis
Score 1 <50% tumor necrosis
Score 2 ≥50% tumor necrosis
Histologic grade (tumor differentiation+mitotic count+ tumor necrosis)
Grade 1 (low grade) Total score: 2 or 3
Grade 2 (intermediate grade) Total score: 4 or 5
Grade 3 (high grade) Total score: 6, 7, or 8
FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; hpf,
high-power field.
Data from Ref. (52).
FIGURE 1 | Histology of a lipoma-like well-differentiated liposarcoma
(hematoxylin and eosin, original magnification 200×).
retroperitoneal myxoid liposarcoma should be regarded with sus-
picion, as most such cases represent either metastatic myxoid
liposarcoma or well-differentiated/dedifferentiated liposarcoma
with myxoid stromal change (57, 58). Pleomorphic liposarcoma,
defined as a high-grade pleomorphic sarcoma showing variable
amounts of lipoblastic differentiation, arise most often in the
limbs of elderly patients and are extremely rare in retroperitoneal
location (59, 60).
FIGURE 2 | Nuclear MDM2 immunohistochemical overexpression in
the atypical adipocytes in a lipoma-like well-differentiated liposarcoma
(original magnification 200×).
FIGURE 3 | Amplification of the MDM2 gene in a well-differentiated
liposarcoma (fluorescence in situ hybridization, FISH).
Well-differentiated liposarcoma is a genetically distinct group
of lesions. With the exception of the spindle cell variant, all well-
differentiated liposarcoma subtypes share the same genetic aber-
ration and are characterized by supernumerary ring and/or giant
rod chromosomes containing amplified segments from the 12q13-
15 region where several proto-oncogenes including murine double
minute type 2 (MDM2), cyclin-dependent kinase 4 (CDK4), high-
mobility AT-hook 2 (HMGA2), and tetraspanin 31 (TSPAN31 or
SAS) are located (61–69). MDM2 is the most frequent amplified
gene, close to 100%, and CDK4 is shown to be amplified in over
90% of cases (70, 71). Co-amplification of MDM2 and CDK4 is a
common feature in well-differentiated liposarcoma and is thought
to be the initiating“driving”factor in fat tumorigenesis, resulting in
proliferation through combined effects upon p53 (by inactivating
TP53) and the cell cycle (by RB1 phosphorylation), respectively. It
has been suggested that CDK4 provides a selection advantage in
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FIGURE 4 | Histology of a dedifferentiated liposarcoma (hematoxylin
and eosin, original magnification 100×).
well-differentiated liposarcoma and may contribute to transfor-
mation as CDK4 negative well-differentiated liposarcoma exhibit
more favorable prognostic features (64, 70–72). Amplification of
MDM2, CDK4, and HMGA2 can be detected by molecular tech-
niques including FISH, PCR, MLPA, or aCGH techniques (68,
73–75). P53 mutations are rarely seen in well-differentiated and
dedifferentiated liposarcomas, but are commonly in pleomorphic
liposarcomas.
Barretina et al. showed 16.7% of pleomorphic liposarcoma
cases had mutations in p53 (76). Similarly, high p53 muta-
tions rates (approximately 60%) were observed in pleomorphic
liposarcoma by Ghadimi et al. (77).
Moreover, identifying MDM2 amplification, as well as over-
expression of the corresponding MDM2 protein by immuno-
histochemistry, has proved an adjunctive tool in the diagnosis
of lipomatous neoplasms, especially in the diagnosis of a well-
differentiated liposarcoma, because MDM2 amplification is absent
in “ordinary” lipomas (Figures 2 and 3) (78–81). Molecular test-
ing should be considered for “relapsing lipomas,” tumors with
questionable cytologic atypia (pathologists tend to overestimate
the degree of cytologic atypia), or for large lipomatous tumors
(>15 cm) without diagnostic cytologic atypia (81).
Dedifferentiated liposarcoma is a biologically fascinating lesion,
in which morphology, genetics, and clinical behavior converge to
define a distinctive clinicopathological entity. The term “tumor
dedifferentiation” as established in 1971 by Dahlin and Beabout,
characterizes “the morphological progression of a low-grade
tumor to a less differentiated neoplasm with a more aggres-
sive behavior” (82). Dedifferentiated liposarcoma is traditionally
defined as “a non-lipogenic high-grade sarcoma arising from
a well-differentiated liposarcoma that confers metastatic poten-
tial.” The term dedifferentiated liposarcoma was first introduced
by Evans in 1979, describing a liposarcoma containing a well-
differentiated liposarcoma component juxtaposed to areas of high-
grade non-lipogenic sarcoma and was believed to occur from
well-differentiated liposarcoma after several years (83). The RP is
the most common location, outnumbering somatic soft tissue by
at least 5/1 (55, 56, 84). More than 90% of dedifferentiated liposar-
coma arises de novo (synchronous), while <10% occurs in recur-
rences (metachronous). Dedifferentiated areas in dedifferentiated
liposarcoma exhibit a wide morphological spectrum (84). Histo-
logically, most cases of dedifferentiated liposarcoma show areas
of high-grade poorly differentiated sarcoma resembling high-
grade myxofibrosarcoma, fibrosarcoma, malignant solitary fibrous
tumor, or pleomorphic sarcoma NOS (Figure 4). In about 5–10%
of cases, the dedifferentiated component shows divergent differen-
tiation featuring myogenic, angiosarcomatous, or osteochondro-
matous components (85–88). Several recent studies have reported
that most sarcomas diagnosed as poorly differentiated sarcomas
and arising in the RP are, in fact, dedifferentiated liposarcomas and
can now be diagnosed as such on the basis of MDM2 amplifica-
tion even in challenging cases of a non-lipogenic undifferentiated
sarcoma without an atypical adipocytic component (89–91). Like
atypical lipomatous tumor/well-differentiated liposarcoma, ded-
ifferentiated liposarcoma is characterized by presence of supernu-
mary ring and/or giant rod chromosomes containing amplified
segments from the 12q13-15 region (55, 56, 62, 63, 65, 66, 84).
Intensive research has identified several oncogenes residing in
this region, including MDM2, CDK4, HMGA2, TSPAN31 (SAS),
YEATS4, miR-26a-2, CPM, OS1, OS9, CHOP (DDIT3), and GLI1
(63). The most evidence, to date, demonstrates an oncogenic
role in dedifferentiated liposarcoma, like the atypical lipoma-
tous tumor/well-differentiated liposarcoma, for MDM2, CDK4,
HMGA2, and TSPAN31 (SAS) (55, 64, 70, 71, 84). Wang et al.
described consistent amplification of the fibroblast growth fac-
tor receptor substrate 2 gene (FRS2) in dedifferentiated (and
well-differentiated) liposarcoma (92). Recently, STAT6 (12q13)
amplification and overexpression was described in a subset of ded-
ifferentiated liposarcoma, further underlining the genomic com-
plexity and heterogeneity of ring and giant marker chromosomes
of this tumor type, particularly concerning amplicons originat-
ing from the chromosomal region 12q13-15 (93, 94). Despite its
typically high-grade morphology, dedifferentiated liposarcoma is
much less aggressive than other types of high-grade pleomorphic
sarcoma (55, 56, 95, 96). Dedifferentiation is associated with a 15–
20% metastatic rate; however, mortality is related more often to
uncontrolled local recurrences than to metastatic spread. There-
fore, it is of clinical importance to distinguish a dedifferentiated
liposarcoma from a de novo high-grade pleomorphic sarcoma of
some other type (97). A recent study by Thway et al. have sug-
gested that the immunohistochemical trio of CDK4, MDM2, and
the cell cycle regulator p16 is an useful ancillary diagnostic tool dis-
tinguishing dedifferentiated liposarcomas from pleomorphic and
myxoid liposarcomas (Figures 5 and 6) (98).
The concept of dedifferentiation in liposarcoma has undergone
an evolution in the last several years and the traditional views
have been modified by the concept of low-grade dedifferentiation
in dedifferentiated liposarcoma. Where it was once assumed that
all dedifferentiated tumors manifested themselves as high-grade,
undifferentiated sarcoma-like lesions, the concept of low-grade
dedifferentiation has increasingly been recognized, with areas
resembling low-grade myxofibrosarcoma, desmoid fibromatosis,
well-differentiated fibrosarcoma, and even dermatofibrosarcoma
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FIGURE 5 | Nuclear MDM2 immunohistochemical overexpression in
dedifferentiated liposarcoma (original magnification 200×).
FIGURE 6 | Nuclear CDK4 immunohistochemical overexpression in
dedifferentiated liposarcoma (original magnification 200×).
protuberans (55, 56, 84). The significance of this lower grade
of progression is, to date, not completely known and is still
controversial. However, there is some suggestion that the lower
grade progression carries a better prognosis than the high-grade
undifferentiated type of dedifferentiated liposarcoma (55).
The mechanisms responsible for progression from well-
differentiated liposarcoma to dedifferentiated liposarcoma are
incompletely understood. Since MDM2 and CDK4 amplifica-
tions are present in both well-differentiated and dedifferentiated
liposarcoma, the presence of these amplifications as such are
not triggers for dedifferentiation in liposarcomas. As a group,
dedifferentiated liposarcomas show more complex chromosomal
aberrations than do well-differentiated liposarcomas. Chromoso-
mal imbalances additionally to the 12q13-q15 amplicon, including
amplifications in 1p32 (including JUN ), 1q21-q24, and/or 6q23
(including the ASK1 or MAP3K5 gene), have been reported to
be more frequent in dedifferentiated liposarcoma than in well-
differentiated liposarcoma (69). Recent studies into the well-
differentiated liposarcoma de-differentiation process have sug-
gested a role for c-Jun N-terminal kinase (JNK ) pathway (99).
The proto-oncogene c-Jun encodes part of the activator protein
transcription factor (AP-1) complex involved in cell proliferation,
transformation, and apoptosis. ASK1 activates JNK ultimately
leading to c-Jun activation and peroxisome proliferator-activated
receptors (PPAR) gamma inactivation. PPAR gamma is involved
in the adipocytic differentiation process and its inhibition may
result in dedifferentiation. Co-amplification of 1p32 and 6q23
that contain c-Jun and apoptosis signaling kinase 1 (ASK1) are
seen in dedifferentiated liposarcoma but not in well-differentiated
liposarcoma (84, 99–103).
TREATMENT
SURGERY
Surgery is the mainstay of treatment of non-metastatic retroperi-
toneal liposarcoma (RLS). Whenever possible, macroscopically
complete resection should be aimed at, often requiring en-bloc
removal of adjacent structures such as the abdominal wall, psoas,
or paravertebral muscles. In an attempt to optimize the surgical
approach to these patients and provide a standardized, repro-
ducible technique, technical guidelines were recently provided by
E-Surge, a master class in sarcoma surgery, and the EORTC soft tis-
sue and bone sarcoma group (104). Areas of uncertainty include
the necessity of pretreatment biopsy, and the impact of surgical
radicality versus disease biology on local control and long-term
survival.
PRETREATMENT BIOPSY
In most patients with RLS, the iconographic appearance (location,
density, displacement rather than invasion of adjacent organs) is
nearly diagnostic and pretreatment biopsy therefore unnecessary.
As a consequence, it has been argued that pretreatment biopsy does
not offer any value in patients with a resectable retroperitoneal
mass (105). In some patients, however, radiology may suggest a dif-
ferent pathology that may not require surgery as the first approach
(lymphoma, Ewing sarcoma, GIST). Also, in patients at risk for
incomplete resection and in whom neoadjuvant radiotherapy is
planned, pretreatment histological confirmation is mandatory. In
these patients, image guided core or fine needle aspiration biopsy
are reliable and safe, and preferred over open or laparoscopic
approaches, which may be associated with a higher risk of tumor
spillage and may compromise future surgical strategy by altering
tissue planes (106–109).
EXTENT OF SURGERY VERSUS TUMOR BIOLOGY
In contrast to limb (lipo)sarcoma, removal of the entire tumor
with a rim of normal tissue is usually precluded in (large) RLS
due to adjacent large vessels, nerves, or bony structures. As a con-
sequence, many patients develop locally recurrent disease in the
abdomen, which constitutes the cause of death in approximately
three out of four patients (Figure 7) (34). Several centers there-
fore advocate liberal compartmental, en-bloc resection of adjacent
organs in order to reduce the risk of local relapse (30, 32). On the
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FIGURE 7 |Typical disease course of dedifferentiated liposarcoma in an
elderly patient, who presented with a recurrent RLS in February 2011
2 years after primary surgery (A). The patient was treated with
neoadjuvant radiotherapy (45 Gy in fractions of 1.8 Gy) and macroscopically
completes resection. In May 2012, a solitary metastasis in the right liver
lobe (B) was treated with RF ablation. In September 2012, a solitary 1.6 cm
metastasis was removed thoracoscopically from the right lower lobe. In
May 2013, a second retroperitoneal recurrence developed (B) for which
repeat macroscopically complete surgery was performed. In September
2014, a small recurrence was noted against the left iliac bone [(C) arrow] for
which additional surgery is planned. No other local or metastatic locations
were noted.
other hand, although all liposarcomas share the amplification of
12q13-15, resulting in overexpression of MDM2 and CDK4, the
molecular biology of the disease is heterogeneous, and likely to be
differing between limb and retroperitoneal disease locations, given
the fact that recent molecular studies highlighted major onto-
genetic differences between normal subcutaneous and visceral
(including retroperitoneal) fat tissue (110). High grade, dedif-
ferentiated tumors are at much higher risk to recur and spread
systemically, and therefore, unlikely to benefit from extensive
surgery (111).
The published surgical experience is entirely based on ret-
rospective analyses and difficult to interpret due to significant
heterogeneity in terms of care setting (monocentric versus mul-
ticentric or multinational), sarcoma type, stage distribution, type
of presentation (primary versus recurrent disease), staging sys-
tem used, and pathology methods used (Table 5). Nevertheless,
some observations are rather consistent. First, as is clear from the
results of multivariate analyses and the associated estimates of the
hazard or risk ratio, advanced tumor grade represents the most
important adverse prognostic factor for overall survival as well as
for local recurrence. Second, macroscopically incomplete, piece-
meal resection, or tumor rupture are associated with a dismal
outcome and should not be attempted unless for symptomatic
reasons. The efficacy of extended, liberal resection is equivo-
cal, while some authors have identified multiorgan resection and
microscopic margin status (R0 versus R1) as independent prog-
nosticators for local recurrence; others found that only tumor
biology (grade) and macroscopically complete resection were asso-
ciated with outcome. Obviously, interpretation of these data is
hampered by the fact that in these large tumors, precise determi-
nation of R0 resection is not a sinecure. When considering the
potential benefit of extensive surgery, it should be noted that a
significant proportion of patients will develop multifocal recur-
rence, including at sites remote from the primary tumor location.
Tseng and coworkers found that as many of 50% of patients
with recurrent RLS presented with multifocal disease; importantly,
type or extent of surgery did not predict recurrence outside of
the resection field on univariate logistic regression analysis (37).
Although tumor spill or incomplete resection may explain mul-
tifocal recurrence, it has been suggested that a “field change” of
the entire intra-abdominal fat tissue may underly the observation
of remote (out-of-field) recurrence (112). Genomic analyses of
normal retroperitoneal fat as well as tumor samples may provide
further insight into this phenomenon.
RADIATION THERAPY
Even after optimal resection of RLS, local recurrence remains com-
mon and constitutes the most frequent cause of death. Therefore,
adjuvant radiation therapy (RT) may constitute a valuable treat-
ment option in order to improve local control, specifically with
involved margins or high-grade tumors. In patients with soft tissue
sarcoma of the extremity, two small randomized trials have shown
that postoperatiive external beam radiotherapy or brachytherapy
improve local control, but do not benefit overall survival (115–
117). In retroperitoneal soft tissue sarcoma, a myriad of small
trials has been published, which show marked variation in RT dose,
fractionation, concurrent use of chemotherapy, delivery method
(external beam or brachytherapy), timing (preoperative, intraop-
erative, or postoperative), and energy carrier (photons, electrons,
protons, or carbon ions) (118).
Preoperative RT is usually regarded as the treatment sequence
of choice. First, preoperative radiation helps to avoid damage to
radiation sensitive structures and organs, which usually fill in the
resection bed after removal of these large tumors. Second, treat-
ment compliance is usually better and related toxicity less in the
preoperative setting. Also, the biological effects of RT are enhanced
in undisturbed, well perfused, and oxygenated tissue.
Table 6 illustrates published data on the use of preoperative
RT in patients with retroperitoneal sarcoma. Most are small, ret-
rospective series describing different histologies and treatment
www.frontiersin.org February 2015 | Volume 2 | Article 4 | 9
                                                         
M
atthyssens
et
al.
R
etroperitonealliposarcom
a
Table 5 | Prognostic factors of local control and overall survival outcome in selected published series of surgically treated retroperitoneal (lipo)sarcoma.
Author N LiSa% CoRes% 5 years
OS/
DSS%
5 years
DFS/
LRFS%
Prognostic factors
Overall survival Local recurrence/DFS
Univariate Multivariate Univariate Multivariate
Significant NS Significant NS Significant NS Significant NS
Kilkenny (113) 63 22 78 48 – – Multivisceral
resection
Gender, biopsy
type
Vascular
involvement
Adjuvant
therapy
Location, race
Compl.
resection
(<0.0001)
Grade (0.001)
Metastatic dis
Multiple
resections
Margin status
Histol type
– – – –
Lewis (5) 500 41 42 54 59 Grade
Margin status
Gender, size
Age, histol type
Grade (2.0–5.0)
Size (1.1–2.7)
Incomplete res
(2.5–6.5)
– Gender, grade
Histol type
Age, size
Margin status
Grade (1.2–3.4)
Histol type
(1.5–4.6)
Stoeckle (36) 165 26 65 46 42 RT, histol type
Complete
resection
– No compl
remission
(1.6–5.1)
Grade 3
(1.5–7.6)
T3 stage
(1.1–3.4)
Size, gender
Location
– – No RT (1.8–6.3)
Grade 3
(1.4–7.3)
T stage, size
Chemotherapy
Histol type
Ferrario (35) 130 41 95 65 – – – Grade (0.001)
Extent of
resection (0.01)
Size – – – –
Gronchi (33) 167 57.5 88 53.6 27.6 – – Grade 3
(3.1–8.8)
RT (0.4–0.9)
Tx period
Size,
chemotherapy
– – Tx period
(0.4–0.9)
Grade 3
(1.5–4.1)
RT (0.4–1.01)
Size
Chemotherapy
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Table 5 | Continued
Author N LiSa% CoRes% 5 years
OS/
DSS%
5 years
DFS/
LRFS%
Prognostic factors
Overall survival Local recurrence/DFS
Univariate Multivariate Univariate Multivariate
Significant NS Significant NS Significant NS Significant NS
Van Dalen (38) 143 38 54 39 22 Age, histol type
Grade,
incomplete res
Distant
metastasis
Locoregional
spread
Grade (1.2–4)
Incomplete res
(1.7–4.2)
– – – Intermediate
grade (1.3–4.9)
Lehnert (21)a 110 53.6 67 49 40 Grade, margin
status
Blood loss
Adjacent organ
invasion
Primary vs
recurrent
Age, size
Grade
(1.3–28.2)
Blood loss
(1.1–4.9)
Age, margin
status
Adjacent organ
invasion
Primary vs
recurrent
Grade
Primary vs
recurrent
Margin status
Adjacent organ
invasion
Size, age
Blood loss
Grade
(2.7–34.6)
Prim vs rec
(0.99–4.4)
Age, size
Margin status
Blood loss
Adj organ
invasion
Bonvalot (15) 382 50 73 57 51 Histol type,
grade
Tumor rupture
Incomplete res
Margin status
Gender, age,
size
RT
# Organs
resected
Grade 3
(2.03–6.3)
Margin status
(1.1–2.7)
Tumor rupture
(1.4–3.3)
Histol type Grade 3, histol
type
No multiorgan
res
Margin status
Tumor rupture
<30 cases/
center
– Grade 3
(1.5–4.6)
No multiorgan
res (1.2–3.9)
Margin status
(1.2–2.9)
Tumor rupture
(1.5–3.6)
# Cases/center
Strauss (26) 200 76 85 68.6 54.6 Grade, size
ALT histol type
Incomplete res
Age, weight
R0 vs R1
Grade 3
(6.5–46.3)
Incomplete res
(1.5–5.8)
Size Grade
Incomplete res
Age, size
Weight
Grade 3 (2.4–9)
Incomplete re
(2.3–5.9)
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Table 5 | Continued
Author N LiSa% CoRes% 5 years
OS/
DSS%
5 years
DFS/
LRFS%
Prognostic factors
Overall survival Local recurrence/DFS
Univariate Multivariate Univariate Multivariate
Significant NS Significant NS Significant NS Significant NS
Gronchi (29) 523 52.7 91 56.8 39.4 – – Age (1.04–1.7)
Size (1.6–3.4)
Grade 3
(9.2–77.9)
Multifocality
(1.4–4.02)
Incomplete res
(1.05–2.75)
Histol type – – Size (1.2–2.2)
Grade 3
(4.1–18.3)
Multifocality
(1.6–4.8)
Histol type
Toulmonde (114)b 586 64.5 76 66 46 – – Age (1.0–1.9)
Male gender
(1.3–2.3)
Grade 3
(2.7–6.2)
Adj organ
invasion
(1.2–2.2)
Piecemeal res
(1.3–3.0)
– – – Male gender
(1.1–2.0)
Adj organ
invasion
(1.2–2.1)
Surgeon
specialization
(0.4–0.7)
Piecemeal res
(1.9–4.5)
Periop RT
(0.4–0.7)
–
aIncludes primary and recurrent RPS.
bPrognostic factors calculated for a subgroup of patients (N=389) who underwent complete resection.
NS, not statistically significant; RT, radiotherapy; ALT, atypical lipomatous tumor; res, resection; vs, versus; LiSa, liposarcoma; CoRes, complete resection; OS, overall survival; DSS, disease-specific survival; DFS,
disease free survival; LRFS, local recurrence free survival. Numbers between brackets represent the 95% confidence interval of the hazard ratio or risk ratio.
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Table 6 | Selected clinical studies of preoperative radiotherapy for retroperitoneal (lipo)sarcoma.
Author N % LiSa Treatment regimen 5 years LRFS 5 years DFS 5 years OS/DSS
Gieschen (120) 37 22 EBRT (45–50 Gy/1.8 Gy)/additional IOERT
(10–20 Gy; N =20)
60.6/83.3 25.6/68.2a 30/74.4a
Pawlik (121) 72 40 MDACC: chemoradiation (18–50.4 Gy with
concurrent doxorubicin) and IOERT (N =35)
60 46 50
U Toronto: EBRT (45 Gy) and postop BT (25 Gy)
Tzeng (122) 16 25 EBRT (45+57.5 Gy boost to volume at risk for
positive margins)
80 @2 years – –
White (123) 27 50 EBRT 45–50 Gy after surgical tissue expander
insertion
80 – 74
Caudle (124) 14 43 EBRT (45–50 Gy); additional IOERT (12.5–15 Gy,
N =5)
50 @2 years – 74 @2 years
Ballo (125) 83f EBRT (50 Gy); additional IOERT (15 Gy, N =18),
additional postop BT (N =2)
40 @10 years 39 @10 years 44 @10 years
Yoon (126) 28c 50 EBRT (50 Gy); additional IOERT (10–12 Gy,
N =12)
90d,e – 87d
Alford (127) 24 50 EBRT (45–50.4 Gy) 81.3 48.9 53.7
McBride (128) 33 48 EBRT (50 Gy); additional postop BT (77.5 Gy,
N =10)
– 45.4 @3 years 63.5 @3 years
Sweeting (129) 18 50 EBRT (45–50 Gy, N =17); additional IOERT
(12.5–20 Gy)
64 – 72
Smith (130) 40 70 EBRT (45–50 Gy/1.8 Gy)/additional postop BT
(20 Gy; N =19)
75/61 – 76b/52b
Stucky (119) 63 68 Surgery alone (N =26) 46 – 60
EBRT (45–50 Gy) and IOERT (10–20 Gy); N =37 89a – 60
Gronchi (131) 83 54 EBRT (45 Gy) with high dose ifosfamide;
additional IOERT (10–12 Gy, N =14)
– 44 59
OS, overall survival; DSS, disease-specific survival; DFS, disease free survival; LRFS, local recurrence free survival; EBRT, external beam radiotherapy; IOERT,
intraoperative electron beam radiotherapy; BT, brachytherapy. MDACC, MD Anderson Cancer Center; U, University;
aStatistically significant.
bSurvival at 10 years.
cIncludes eight patients who underwent postoperative RT.
dSurvival at 3 years.
eIn patients with primary tumors.
fIncludes 33 patients who underwent postop RT; LiSa, liposarcoma.
methods. Local control seems, on average, somewhat better com-
pared to surgery alone series. Although the small numbers pre-
clude any robust conclusion, most authors did not find any benefit
of adding either IOERT or postoperative BT to the external beam
RT. Only one small study compared surgery alone with preop-
erative external beam and intraoperative RT followed by surgery,
and found that the combined modality resulted in improved local
control without any difference in overall survival (119). Several
authors have scrutinized data from the surveillance, epidemiol-
ogy, and end results (SEER) database in an attempt to define the
role of adjuvant RT in RLS (Table 7). The results are difficult
to compare due to differences in inclusion period, inclusion crite-
ria, case mix, and analytical method. As a general finding, adjuvant
radiotherapy either did not benefit survival or did so in a subgroup
of stage I patients only. Of note, the large majority of patients
treated with radiotherapy were administered this treatment in the
postoperative period.
To date, no randomized trials have been completed or pub-
lished comparing surgery alone with combined surgery and RT.
The American College of Surgeons Oncology Group (ACOSOG)
initiated a trial (Z9031) in 2004 comparing surgery alone versus
fractionated RT followed by surgery. The primary endpoint was
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Table 7 | Studies based on data from the surveillance, epidemiology, and end results (SEER) database in an attempt to define the role of
adjuvant radiotherapy in retroperitoneal sarcoma.
Author Inclusion N Inclusion criteria Statistical methods Significant
covariates
for OS/DSS
RT
Porter (132) 1973–2001 1226 surgery
428 surgery with RT
(85.5% of RT postop)
Age ≥18 Logistic regression
(use of RT)
– Adjuvant radiotherapy
use varies significantly
with age, race, and
geographical location
Nathan (133) 1988–2005 1365 Curative intent
surgery
Cox regression Age, sex, grade,
histology
Unadjusted Cox
analysis: HR for OS
0.78–1.15
Zhou (134) 1988–2005 1574 Age ≥18 Cox regression
Stratified for AJCC
stage
Surgery, age, sex,
stage
Stage I: HR for OS
0.25–0.96
Stage II/III: HR for OS
0.58–1.06
Tseng (135) 1988–2004 1130 surgery
373 surgery with RT
(80.4% of RT postop)
Age ≥18
Patients underwent
surgery
Cox regression Age, sex, histology,
grade
Complete resection
Cox regression: HR for
OS 0.78–1.09 overall
OS benefit in MFH
(P =0.002) and
dedifferentiated
liposarcoma (P =0.08)
in univariate analysis
Choi (136) 1988–2006 558 surgery
204 surgery with RT
(80% of RT postop)
Age ≥20, single
malignancy
Curative intent
surgery
Cox regression;
propensity score
matching
Age, sex, grade,
stage
Cox regression: HR
for DSS 0.87–1.56
After PS matching: no
difference in DSS
(P =0.35) or OS
(P =0.1)
OS, overall survival; DSS, disease-specific survival; HR, hazard ratio; MFH, malignant fibrous hstiocytoma; PS, propensity score.
progression free survival at 5 years. This trial was terminated due to
poor accrual. The European Organization for Research and Treat-
ment of Cancer (EORTC) protocol 62092, which started in 2012,
randomizes patients to either en-bloc surgery alone versus frac-
tionated RT (50.4 Gy in 28 fractions) followed by en-bloc surgery.
The primary endpoint is abdominal recurrence free survival. With
a planned sample size of N = 256, completion of the inclusion
period will take at least until 2019.
SYSTEMIC THERAPY
Chemotherapy has an established role in the palliative manage-
ment of advanced or metastatic soft tissue sarcoma. Active agents
include the anthracyclines (doxorubicin and epirubicin) and the
alkylating agent ifosfamide (137). In patients with resistant disease,
gemcitabine, docetaxel, trabectedin, and pazopanib were estab-
lished as effective second or third line options over the last decade
(138). STS are a very heterogeneous group, and chemosensitivity
is determined by histological type and grade. Examples include
the response of angiosarcomas to paclitaxel and pegylated liposo-
mal doxorubicin, the response of leiomyosarcomas to gemcitabine
and docetaxel, and the response of desmoid tumors to liposo-
mal doxorubicin (138). Similarly, the response of liposarcoma
to chemotherapy differs according to histological subtype and
grade. Investigators from the Royal Marsden Hospital investi-
gated response to chemotherapy in 88 patients with liposarcoma
(43% located in the RP) (139). They found a significantly higher
response rate in myxoid liposarcoma compared to all other liposar-
comas (48 versus 18%, P = 0.012). The response rate was 25% in
dedifferentiated liposarcoma, while none of the well-differentiated
liposarcomas responded. Also, response was significantly better in
patients with liposarcoma of the upper limb (75%) or lower limb
(36%) compared to other locations (18%). Italiano and coworkers
reported the role of chemotherapy in unresectable and/or metasta-
tic well-differentiated and dedifferentiated liposarcoma (77.5%
retroperitoneal) based on retrospective analysis of data from 10
centers (139). Seventy-three percent of the included 208 patients
had at least one metastatic site. Using RECIST criteria, response
was complete in 1% and partial in 11%, while stable disease and
progression were seen in 48 and 39%, respectively. No difference
was observed in response rate between WD and DD liposarcoma.
Because well-differentiated liposarcoma and dedifferentiated
liposarcoma respond poorly to systemic chemotherapy, it is essen-
tial that novel molecular targets will be identified to provide new
possibilities for therapies. The reported results of recent clinical
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Table 8 | Molecular therapeutic targets and agents in soft tissue sarcoma.
Molecule Target/mechanism Liposarcoma histologic
subtype
Clinical phase
Marine derived compounds Trabectedin (145–147) Binding of DNA minor groove;
direct interaction with
FUS-CHOP fusion protein
Myxoid/round cell
liposarcoma
Phase II, retrospective
and neoadjuvant
Eribulin (148) Microtubule inhibitor Dedifferentiated
liposarcoma
Phase II
MDM2 antagonists RG7112 (143, 149) p53-MDM2 inhibitor Well-differentiated and
dedifferentiated
liposarcoma
Phase I (neoadjuvant)
RG7388 (150) p53-MDM2 inhibitor Well-differentiated and
dedifferentiated
liposarcoma
Phase I
CDK4 antagonists Flavopiridol (151) Pan-CDK inhibitor, including
CDK4
Well-differentiated and
dedifferentiated
liposarcoma
Phase I
PD 0332991 (142) CDK4/6 inhibitor Well-differentiated and
dedifferentiated
liposarcoma
Phase I
Other Troglitazone (152)
Rosiglitazone (153)
Efatutazone (154)
PPAR gamma agonist All liposarcoma types Phase I, II
Nelfinavir (155, 156) SREBP-1 inhibitor Well-differentiated and
dedifferentiated
liposarcoma
Phase I
Sunitinib (157) Tyrosine kinase receptor
inhibitor
All liposarcoma types Phase II
Panobinostat (158) Histone deacetylase inhibitor All liposarcoma types Phase II
trials for novel systemic therapies in advanced liposarcoma are
overall encouraging. In the past decade, results from clinical tri-
als have identified several novel systemic therapies in soft tissue
sarcoma, many of which have potential efficacy in liposarcoma (5,
140). In contrast to conventional cytotoxic chemotherapies, which
are non-specific, the majority of these novel therapies are based on
the understanding of disease biology inherent to a given sarcoma
histology, in many cases targeting a specific, aberrant genetic, or
molecular pathway. For the majority of novel therapies, treatment
efficacy is heavily dependent on subtype. Reported human studies
and clinical trials for novel systemic therapies in liposarcoma are
summarized in Table 8. Targeting MDM2 or CDK4 (MDM2 and
CDK4 antagonists) in well-differentiated liposarcoma and dedif-
ferentiated liposarcoma has been of interest for several years (5,
140–143). Based on the fact that well-differentiated liposarcoma
and dedifferentiated liposarcoma are relatively resistant to sys-
temic chemotherapy, MDM2 and CDK4 targeted therapy may be a
very promising approach, especially for advanced or unresectable
well-differentiated and dedifferentiated liposarcoma. A class of
imidazoline compounds, termed nutlins, has been identified as
potent and selective small-molecule MDM2 inhibitors. RG7112
(Hoffmann-La Roche) (Phase I, neoadjuvant) is a member of the
nutlin family and is the first MDM2 antagonist to be assessed
clinically. RG7112 is a potent inhibitor of p53-MDM2 bind-
ing that effectively stabilizes p53 protein, activates p53 signaling,
and inhibits cancer cell growth (140, 141). Flavopiridol-CDK4
inhibitor and PD0332991-CDK4/CDK6 inhibitor (Pfizer) (Phase
I) are potent CDK4 inhibitors, preventing downstream phospho-
rylation of the retinoblastoma (RB) protein. CDK4 inhibition
would thus restore native cell cycle regulation and prevent uncon-
trolled tumor cell proliferation (140,143). Several other interesting
candidate targets for novel systemic therapies, including YEATS4,
c-jun, JNK, and others, have been reported but have not yet been
tested, to our knowledge, in the setting of a clinical trial (140,
144). PPAR are critical regulators of normal adipocyte differen-
tiation. PPAR gamma is one of the three isoforms that forms a
heterodimeric complex with the retinoid X receptor to regulate
transcription of adipocyte-specific genes involved in the terminal
adipocyte pathway. Activation of PPAR gamma by PPAR gamma
agonists (troglitazone, rosiglitazone, efatutazone; phase I and II)
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represents an attractive target, particularly in dedifferentiated
liposarcoma, myxoid/round cell liposarcoma and pleomorphic
liposarcoma, as a mechanism to revert these subtypes to a well
differentiated phenotype with potentially more indolent disease
progression (5).
Tyrosine kinase receptors are a diverse family of surface mol-
ecules recognized for their critical role in regulating multiple
aspects of carcinogenesis, tumor cell proliferation, and disease pro-
gression (e.g., angiogenesis, metastasis) across many solid tumor
types. In the presence of a specific growth factor ligand, tyro-
sine kinase receptors and their associated downstream molecules
are frequently over-expressed or mutated, leading to constitutive
activation or aberrant signaling. In a single institution study of
48 patients at the Moffitt Cancer Center, Tariq Mahmood et al.
reported impressive efficacy with sunitinib, especially for liposar-
coma (157). It is unclear why sunitinib, but not pazopanib or
sorafenib, has anti-tumor activity in liposarcoma despite having
similar molecular targets (159, 160).
CONCLUSION
Retroperitoneal liposarcoma is a rare tumor, and exhibits consid-
erable histological heterogeneity. Adequate staging and grading
is essential in guiding the therapeutic approach. Macroscopically
complete resection offers the best chance of prolonged recurrence
free survival. The value of extensive, “compartmental” resection
in these patients is at present not well defined, but influenced by
disease biology. Preoperative radiotherapy may lower the risk of
locally recurrent disease, and a prospective, randomized EORTC
study is currently open for inclusion. In parallel with the unravel-
ing of the molecular pathways underlying sarcoma genesis, several
targeted agents are in active development that may contribute to
the available systemic treatment options in the near future.
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